ArticleJournal of translational medicine2026
ACOT9, a mitochondrial metabolism-related gene, promotes ROS-associated epithelial remodeling in laryngeal squamous cell carcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resistance-oriented immunometabolic circuits in laryngeal squamous cell carcinoma: glycolysis-lactate signaling, mitochondrial stress, and tumor-myeloid crosstalk.Frontiers in immunology · 2026Review
- An anoikis-related four-gene prognostic signature and functional characterization of ANXA5 in laryngeal squamous cell carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaryngeal squamous cell carcinoma (LSCC) is characterized by mitochondrial metabolic reprogramming, but its prognostic significance and underlying molecular mechanisms remain insufficiently understood. This study aimed to develop a prognostic mitochondrial metabolism-related genes signature (MMGS) for LSCC and to investigate the biological role of ACOT9 in tumor progression.
methodsDifferentially expressed mitochondrial metabolism-related genes (MMGs) were identified from TCGA-LSCC data. A MMGS was established through machine-learning evaluation of 178 model combinations and validated in the TCGA training cohort, TCGA test cohort, and the independent GSE65858 dataset. To explore its biological relevance, immune microenvironment analysis, single-cell RNA sequencing analysis of GSE290927, scTenifoldKnk-based virtual knockout analysis, and a series of experimental assays, including immunohistochemistry, immunofluorescence, qRT-PCR, Western blotting, ROS detection, CCK-8, wound-healing, and apoptosis assays, were performed to characterize immune features, cellular heterogeneity, and the functional role of ACOT9.
resultsThe MMGS demonstrated excellent prognostic performance, with a C-index greater than 0.7388, and independently predicted overall survival in LSCC patients (multivariate Cox, p < 0.05). High-risk patients exhibited increased M0 macrophage infiltration, impaired T-cell co-stimulation, downregulated co-stimulatory molecules, and enrichment of drug metabolism-related pathways. Single-cell analysis revealed elevated MMGS scores in LSCC epithelial and myeloid cells, while ACOT9 was markedly upregulated in malignant epithelial subtypes and positively correlated with stemness (R = 0.18, p < 0.01). Virtual knockout of ACOT9 in epithelial cells identified LAMC2 and KRT17 as the two most significantly perturbed genes, and enrichment analyses indicated a downstream epithelial stress-remodeling network involving keratinization, extracellular matrix organization, inflammatory/immune signaling, and lipid inflammatory pathways. Experimental validation confirmed ACOT9 overexpression, mitochondrial colocalization with TOM20, and elevated mitochondrial ROS levels in LSCC tissues and cells. Furthermore, mitochondrial ROS scavenging or ACOT9 knockdown significantly reduced cell viability and migration while promoting apoptosis.
conclusionsMMGS is a robust and reliable prognostic tool for LSCC. ACOT9 functions as a mitochondrial-associated oncogenic factor that may promote LSCC aggressiveness through a mitochondrial ROS-dependent epithelial remodeling program, highlighting its potential as a therapeutic target for risk-stratified clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.